Over 150 oncologists choose their preference for combination regimens in metastatic ccRCC based on current data in the ...

A study compares second-look laparoscopy and circulating tumor DNA (ctDNA) to detect residual ovarian cancer and predict ...

Dordaviprone received accelerated FDA approval for H3 K27M-mutant diffuse midline glioma, an aggressive brain tumor, making ...

Welcome to this week's edition of The Targeted Pulse, your clinical-focused wrap-up of the most impactful news and research ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

An MD Anderson team led by Amir Jazaeri, MD, takes a pioneering approach to finding residual ovarian cancer cells.

Robert L. Ferris, MD, PhD, editor-in-chief of Targeted Therapies in Oncology, discusses his monthly column in this episode of ...

A study shows talquetamab is a safe, effective bridge for high-risk patients, potentially improving outcomes and mitigating ...

A new study suggests the MAGIC Composite Response metric, which combines clinical and biomarker data, improves prediction of ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Emerging treatments for low-grade serous ovarian cancer and platinum-resistant disease offer new hope, with promising data ...

Mabwell's 7MW4911 receives FDA IND clearance, paving the way for clinical trials targeting advanced GI cancers with promising ...